Efficacy and safety of 1064-nm fractional picosecond laser (FxPico) treatment for hypertrophic and atrophic post-mastectomy scars in transmen. Atrophic scar, Female-to-male transgender, Hypertrophic scar, Picosecond laser, Post-mastectomy scar, Transgender men, and Transmen.
Conditions
Interventions
Fractional picosecond 1064-nm laser (EnlightenTM System
Cutera Inc., Brisbane, CA) with microlens array (MLA) for 4 sessions at 4-week intervals using the following parameters: spot size 10 mm, fluence 0.80 to 1.0 J/cm2, frequency 5 to Hz, and 3 to 4 passe
Fractional picosecond laser,No treatment
Sponsors
Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Transmen wth symmetrical hypertrophic or atrophic mastectomy scars evaluated by a board-certified dermatologist were participated in the study.
Exclusion criteria
Exclusion criteria: Exclusion criteria included 1) severe comorbidities, 2) co-occurring skin infection or inflammation or open wound or acne at the scar site, 3) history of immunodeficiency, skin cancer, coagulopathy, or recurrent herpes infection, 4) pregnancy or breastfeeding, and 5) history of scar treatment within 3 months prior to the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical scar improvement 0, 1, 2, 3, 4, 6, 9 months Modified Vancouver Scar Scale | — |
Secondary
| Measure | Time frame |
|---|---|
| Scar texture/roughness 0, 1, 2, 3, 4, 6, 9 months Antera 3D,Scar melanin level 0, 1, 2, 3, 4, 6, 9 months Antera 3D,Scar hemoglobin level 0, 1, 2, 3, 4, 6, 9 months Antera 3D,Participant satisfaction 9 months VAS,Histopathological changes 0, 9 months H&E, Alcian blue, VVG | — |
Countries
Thailand
Contacts
Public ContactSuthinee Rutnin
Faculty of Medicine, Ramathibodi hospital
Outcome results
None listed